Basic Information
Tepadina
Regulatory Information
EMEA/H/C/001046
March 15, 2010
December 17, 2009
22
October 21, 2024
Company Information
Italy
Via Galileo Galilei, 19 20867 Caponago (MB)
Adienne SRL
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication TEPADINA is indicated, in combination with other chemotherapy medicinal products: \- with or without total body irradiation (TBI), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients; \- when high dose chemotherapy with HPCT support is appropriate for the treatment of solid tumours in adult and paediatric patients.
Overview Summary
This is a summary of the European Public Assessment Report (EPAR) for Tepadina. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Tepadina.